Q3 EPS Estimates for Upstream Bio Lowered by HC Wainwright

Upstream Bio, Inc. (NASDAQ:UPB) – Investment analysts at HC Wainwright dropped their Q3 2026 EPS estimates for Upstream Bio in a research note issued to investors on Wednesday, August 12th. HC Wainwright analyst M. Caufield now expects that the company will post earnings of ($0.79) per share for the quarter, down from their previous estimate of ($0.73). HC Wainwright currently has a “Buy” rating and a $36.00 target price on the stock. The consensus estimate for Upstream Bio’s current full-year earnings is ($2.87) per share. HC Wainwright also issued estimates for Upstream Bio’s Q4 2026 earnings at ($0.82) EPS, FY2026 earnings at ($3.09) EPS, FY2027 earnings at ($3.31) EPS, FY2028 earnings at ($3.13) EPS, FY2029 earnings at ($3.56) EPS and FY2030 earnings at ($3.84) EPS.

Upstream Bio (NASDAQ:UPB) last released its quarterly earnings data on Tuesday, August 11th. The company reported ($0.73) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.74) by $0.01. The business had revenue of $0.77 million for the quarter, compared to analysts’ expectations of $0.56 million. Upstream Bio had a negative net margin of 4,955.67% and a negative return on equity of 45.92%.

Other equities research analysts have also issued research reports about the stock. Weiss Ratings restated a “sell (e+)” rating on shares of Upstream Bio in a research note on Monday, August 3rd. JPMorgan Chase & Co. lowered Upstream Bio from an “overweight” rating to a “neutral” rating and lowered their price target for the company from $35.00 to $8.00 in a report on Friday, June 12th. Truist Financial cut their price objective on Upstream Bio to $25.00 and set a “buy” rating for the company in a report on Tuesday. Finally, Mizuho cut their price target on shares of Upstream Bio from $51.00 to $50.00 and set an “outperform” rating for the company in a report on Thursday, May 14th. Four analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $29.50.

Upstream Bio Price Performance

Upstream Bio stock opened at $6.91 on Friday. The firm has a 50-day moving average price of $6.80 and a two-hundred day moving average price of $9.92. The firm has a market capitalization of $378.46 million, a price-to-earnings ratio of -2.38 and a beta of 1.26. Upstream Bio has a 52-week low of $5.85 and a 52-week high of $33.68.

Institutional Trading of Upstream Bio

A number of hedge funds have recently bought and sold shares of the company. Invesco Ltd. increased its position in shares of Upstream Bio by 6.4% in the second quarter. Invesco Ltd. now owns 16,300 shares of the company’s stock worth $179,000 after acquiring an additional 985 shares in the last quarter. GF Fund Management CO. LTD. purchased a new position in Upstream Bio during the 4th quarter worth approximately $29,000. Torren Management LLC purchased a new position in Upstream Bio during the 4th quarter worth approximately $30,000. JPMorgan Chase & Co. raised its stake in Upstream Bio by 8.4% during the 2nd quarter. JPMorgan Chase & Co. now owns 16,469 shares of the company’s stock valued at $181,000 after purchasing an additional 1,275 shares during the period. Finally, Legal & General Group Plc raised its stake in Upstream Bio by 83.0% during the 2nd quarter. Legal & General Group Plc now owns 3,174 shares of the company’s stock valued at $35,000 after purchasing an additional 1,440 shares during the period.

About Upstream Bio

Upstream Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation prophylactic vaccines and immuno-oncology therapies. Leveraging a proprietary viral vector platform, the company aims to deliver optimized antigen payloads that stimulate robust and durable immune responses against both infectious diseases and cancer targets. Upstream Bio’s approach emphasizes safety, manufacturability and potential for rapid scale-up to address emerging public health challenges.

The company’s research and development pipeline includes multiple viral vector-based candidates in early clinical and preclinical stages.